Clinical value of tumor mutational burden for neoadjuvant and adjuvant immune checkpoint inhibitor in early-stage non-small cell lung cancer
Journal for ImmunoTherapy of Cancer · 2026-03 · 14 (3) · e014168
DOI: 10.1136/jitc-2025-014168 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 31.03.2026. Verfasst von Julia C F Quintanilha und 5 weiteren Autor:innen. Beteiligte Einrichtung: Foundation Medicine Inc, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Carcinoma, Non-Small-Cell Lung, Neoadjuvant Therapy. Die Arbeit nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Foundation Medicine.
Abstract (Originalsprache)
Tumor mutational burden (TMB) and PD-L1 are established biomarkers for guiding immune checkpoint inhibitor (ICI) therapy in advanced non-small cell lung cancer (NSCLC). As ICI use expands into early-stage disease, we explored the feasibility of using TMB, which can be determined via a comprehensive genomic profiling assay along with EGFR and ALK genomic alterations, as a biomarker for outcomes in both neoadjuvant and adjuvant settings. TMB-high status (≥10 mut/Mb) showed a numerically higher, but not statistically significant, rate of pathological complete response among patients receiving neoadjuvant ICI and significantly associated with more favorable time to recurrence in patients receiving adjuvant ICI, particularly among patients with PD-L1 expression
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Foundation Medicine Inc, Boston, Massachusetts, USA.
- Foundation Medicine Inc, Boston, Massachusetts, USA rhuang@foundationmedicine.com.
Förderung
- Foundation Medicine
Zitieren
APA
C F Quintanilha, J., Li, G., Graf, R. P., Gasco, A., Mitchell, J., & Huang, R. S. P. (2026). Clinical value of tumor mutational burden for neoadjuvant and adjuvant immune checkpoint inhibitor in early-stage non-small cell lung cancer. Journal for ImmunoTherapy of Cancer, 14(3), e014168. https://doi.org/10.1136/jitc-2025-014168
Vancouver
C F Quintanilha J, Li G, Graf RP, Gasco A, Mitchell J, Huang RSP. Clinical value of tumor mutational burden for neoadjuvant and adjuvant immune checkpoint inhibitor in early-stage non-small cell lung cancer. Journal for ImmunoTherapy of Cancer. 2026;14(3):e014168. doi:10.1136/jitc-2025-014168
BibTeX
@article{CFQuintanilha2026,
author = {C F Quintanilha, Julia and Li, Gerald and Graf, Ryon P and Gasco, Amaya and Mitchell, Jerry and Huang, Richard S P},
title = {Clinical value of tumor mutational burden for neoadjuvant and adjuvant immune checkpoint inhibitor in early-stage non-small cell lung cancer},
journal = {Journal for ImmunoTherapy of Cancer},
year = {2026},
volume = {14},
number = {3},
pages = {e014168},
doi = {10.1136/jitc-2025-014168}
}
EUVIMED